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ORIGINAL ARTICLE
Antrodia cinnamomea reduces obesity and modulates the gut
microbiota in high-fat diet-fed mice
C-J Chang1,2,3,4,14, C-C Lu5,14, C-S Lin1,2,3,4,14, J Martel1,2, Y-F Ko6,7, DM Ojcius1,2,8, T-R Wu3, Y-H Tsai3, T-S Yeh9, J-J Lu3,10,
H-C Lai1,2,3,4,10,11,12 and JD Young1,2,6,7,13
BACKGROUND: Obesity is associated with gut microbiota dysbiosis, disrupted intestinal barrier and chronic inflammation. Given
the high and increasing prevalence of obesity worldwide, anti-obesity treatments that are safe, effective and widely available would
be beneficial. We examined whether the medicinal mushroom Antrodia cinnamomeamay reduce obesity in mice fed with a high-fat
diet (HFD).
METHODS: Male C57BL/6J mice were fed a HFD for 8 weeks to induce obesity and chronic inflammation. The mice were treated
with a water extract of A. cinnamomea (WEAC), and body weight, fat accumulation, inflammation markers, insulin sensitivity and the
gut microbiota were monitored.
RESULTS: After 8 weeks, the mean body weight of HFD-fed mice was 39.8 ± 1.2 g compared with 35.8 ± 1.3 g for the HFD+1%
WEAC group, corresponding to a reduction of 4 g or 10% of body weight (Po0.0001). WEAC supplementation reduced fat
accumulation and serum triglycerides in a statistically significant manner in HFD-fed mice. WEAC also reversed the effects of HFD
on inflammation markers (interleukin-1β, interleukin-6, tumor necrosis factor-α), insulin resistance and adipokine production (leptin
and adiponectin). Notably, WEAC increased the expression of intestinal tight junctions (zonula occludens-1 and occludin) and
antimicrobial proteins (Reg3g and lysozyme C) in the small intestine, leading to reduced blood endotoxemia. Finally, WEAC
modulated the composition of the gut microbiota, reducing the Firmicutes/Bacteroidetes ratio and increasing the level of
Akkermansia muciniphila and other bacterial species associated with anti-inflammatory properties.
CONCLUSIONS: Supplementation with A. cinnamomea produces anti-obesogenic, anti-inflammatory and antidiabetic effects in
HFD-fed mice by maintaining intestinal integrity and modulating the gut microbiota.
International Journal of Obesity (2018) 42, 231–243; doi:10.1038/ijo.2017.149
INTRODUCTION
Obesity is associated with reduced longevity and poor quality of
life.1 The prevalence of overweight and obesity has increased in
developed and developing countries in recent years.2 Epidemio-
logical evidence suggests that obesity is closely associated with
many chronic diseases, including type 2 diabetes mellitus, cancer
and cardiovascular disease.3 For these reasons, the treatment of
obesity and its complications has become a major public health
issue and novel treatment strategies would be highly beneficial.
The adipose tissues of obese individuals secrete pro-
inflammatory cytokines—also called adipokines—which include
tumor necrosis factor-α (TNF-α), interleukin (IL)-1β, IL-6 and
monocyte chemoattractant protein-1 (MCP-1).4 Pro-inflammatory
adipokines not only promote systemic inflammation but also
insulin resistance which is associated with the development of
type 2 diabetes.3 Regulation of adipokine expression is thus critical
to reduce chronic inflammation and insulin resistance in obese
animals and humans.
Medicinal mushrooms have been widely used as folk medicine
in Asia for the prevention and treatment of human diseases.5,6
Antrodia cinnamomea Chang and Chou (also called Antrodia
camphorata or Taiwanofungus camphoratus) is a rare and unique
fungus that is found in the forests of Taiwan.7 Previous studies
have shown that A. cinnamomea possesses anti-cancer,8 immuno-
modulatory9 and hepato-protective properties.10 We showed
earlier that an ethanol extract of A. cinnamomea suppresses
NLRP3 inflammasome activation and secretion of pro-
inflammatory IL-1β and IL-18 in macrophages.11 A. cinnamomea
also reduces plasma triglycerides, low-density lipoproteins and
total cholesterol in obese hamsters.12 Similarly, ergostatrien-3β-ol,
a compound isolated from an ethanol extract of A. cinnamomea,
reduces body weight, hyperlipidemia and diabetes symptoms in
mice fed with a high-fat diet (HFD).13 In addition, the triterpenoid
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Figure 1. WEAC supplementation reduces body weight and fat accumulation in HFD-fed mice. Chow-fed mice (n= 21) and HFD-fed mice
(n= 15) were treated daily with 200 μl of either double-distilled water as control or WEAC at 0.1% (n= 15) or 1% (w/v) (n= 15) by intragastric
gavage for 8 weeks. Effects of WEAC treatment on body weight (a), relative and absolute body weight gain (b and c), epididymal fat (d),
subcutaneous fat (e), epididymal adipocyte size (f) and serum triglycerides (g). Parameters shown in c–g were measured after eight weeks of
feeding. In f, adipocyte size was estimated using Adiposoft from the ImageJ software. Scale bars, 50 μm. Data are expressed as means± s.d.
from three independent experiments. Body weight differences in a and b were analyzed using two-way ANOVA Bonferroni post hoc test
(##Po0.01 for HFD+0.1% WEAC vs HFD; ***Po0.001 and ****Po0.0001 for HFD+1% WEAC vs HFD). Graph bars with different letters on top
correspond to statistically significant results (Po0.05) based on Bonferroni post hoc one-way ANOVA analysis.
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compound dehydroeburicoic acid isolated from A. cinnamomea
shows antidiabetic and anti-hyperlipidemia activities in
streptozotocin-induced diabetic mice.14 Although these observa-
tions suggest that A. cinnamomea may contain hydrophobic
compounds that produce anti-obesity effects, the effects and
mechanism of action of A. cinnamomea water extract on HFD-fed
mice have not been examined in detail so far.
Recent studies indicate that the gut microbiota is involved in
the development of obesity in animals and humans.15 The
community of intestinal microbiota is involved in energy
regulation, vitamin production and nutrient harvest.16 In obese
mice, the intestinal microbiota community contains a larger
population of Firmicutes and a smaller proportion of Bacteroidetes
compared with lean animals.15 A recent study has shown that the
gut microbiota of human obese twins induces weight gain and fat
deposition following transplantation into mice fed with a low-fat
diet.17 Moreover, the bacterium Akkermansia muciniphila protects
against obesity and inflammation in HFD-fed mice by improving
intestinal barrier integrity and altering adipose tissue
metabolism.18 In addition to changes produced in the gut
microbiota, HFD feeding for 4 weeks reduces intestinal integrity
and increases endotoxemia owing to the translocation of bacterial
lipopolysaccharides (LPS) from the gut microbiota into the
blood.19 LPS found in the blood in turn induces systemic low-
grade inflammation and insulin resistance.20
Targeting the gut microbiota with antibiotics, prebiotics and
probiotics has been shown to produce beneficial effects on
obesity.21 For instance, specific antibiotic treatment modulates the
gut microbiota and reduces obesity, endotoxemia and the cecal
content of LPS in both HFD-fed mice and leptin-deficient mice.19
Administration of probiotics affects host energy metabolism and
signaling, and reduces white adipose tissues and blood endotox-
emia in HFD-fed mice.22 Prebiotics are non-digestible, fermentable
carbohydrates and fibers that reduce body weight and exert anti-
inflammatory effects, mainly by enhancing the growth of
beneficial bacteria found in the gut.23 Prebiotics treatment not
only alters the structure of the gut microbiota but also improves
intestinal permeability and systemic endotoxemia.24 In a previous
study, we showed that polysaccharides isolated from the
medicinal mushroom Ganoderma lucidum act as prebiotics and
reduce obesity and inflammation by modulating the composition
of the gut microbiota.25 Our previous study prompted us to
examine the effects of herbal remedies and medicinal mushrooms
on obesity and type 2 diabetes.26
In the present study, we show that a water extract of
A. cinnamomea (WEAC) reduces body weight, insulin resistance
and inflammation in HFD-fed mice. WEAC treatment not only
maintains intestinal barrier integrity but also modulates the gut
microbiota, increasing A. muciniphila and other bacterial species
associated with anti-inflammatory effects. Our findings thus
demonstrate that WEAC may be useful for the treatment of
obesity and its complications.
MATERIALS AND METHODS
Preparation of A. cinnamomea water extract
The A. cinnamomea strain used in the present study was initially selected
and characterized by Chang Gung Biotechnology. Based on PCR analysis
and sequencing of rDNA and internal transcribed spacers (ITS-1 and ITS-2),
the strain showed 99.7% homology with a type strain (BCRC strain
AJ496398; Bioresource Collection and Research Center, Hsinchu, Taiwan).
WEAC was prepared by adding 400 g of dried A. cinnamomea mycelium
powder (containing 1.5% polysaccharides and 5% triterpenoids) into 10
liters of double-distilled water, followed by incubation at 122 °C for 30 min
with gentle agitation. The mixture was centrifuged at 5900 g for 30 min at
4 °C and the supernatant was concentrated using a vacuum centrifuge to
obtain a final volume of 2 liters. The solution was autoclaved at 121 °C for
20 min. To determine the final concentration of water-soluble material
found in the WEAC solution, the solvent was evaporated and the weight of
the residual material was determined (10%, w/v or 10 g per 100 ml). For
the experiments, WEAC was diluted at 0.1% and 1% (w/v) as indicated in
the figures.
Animals
Eight-week-old male C57BL/6J mice with similar initial body weight were
randomly assigned to four groups (15–21 animals per group) maintained in
groups of three to five animals per cage. (See the figure legends for the
number of animals or samples used in each experiment). We placed mice
on standard chow diet (13.5% of energy from fat; LabDiet 5001; LabDiet,
St Louis, MO, USA) and high-fat diet (60% of energy from fat; TestDiet 58Y1;
TestDiet, St Louis, MO, USA) for 8 weeks and monitored body weight. Mice
were fed with either chow diet or HFD combined with daily administration
of 200 μl of either water or WEAC at 0.1% or 1% (w/v) by intragastric
gavage, corresponding to doses of 0.009 and 0.09 g kg− 1 per day,
respectively (the average mouse body weight at the start of the
experiment was 22.6 g; see Figures 1a, Week 0). The organs, tissues and
serum samples of each mouse were collected for subsequent analyses
done without blinding. No animals were excluded from the analyses.
Animals were housed and treated according to a protocol approved by the
Institutional Animal Care and Use Committee of Chang Gung University
(IACUC; Approval No. CGU15-006). All experiments were performed
according to the guidelines.
Antibodies
Primary antibodies against Akt (clone C67E7; #4691), phosphorylated Akt
(P-Akt; phosphorylation on serine 473; clone D9E; #4060), nuclear factor of
kappa light polypeptide gene enhancer in B cells inhibitor alpha (IkB-α;
#9242), JNK (c-Jun N-terminal; #9252), phosphorylated JNK (phosphoryla-
tion on threonine 183 and tyrosine 185; clone 81E11, #4668), total 5’
adenosine monophosphate-activated protein kinase-α (T-AMPK-α; clone
23A3, #2603) and phosphorylated AMPK-α (P-AMPK-α; phosphorylation on
threonine 172; clone 40H9; #2535) were purchased from Cell Signaling
(Danvers, MA, USA) and diluted 1:1000. Antibodies against β-actin (NB600-
501) and horseradish peroxidase-conjugated secondary anti-mouse
immunoglobulin G (sc-2005) were purchased from Novus Biologicals
(Littleton, CO, USA) and Santa Cruz Biotechnology (Santa Cruz, CA, USA),
respectively and diluted 1:20000. Fluorescein-isothiocyanate-conjugated
anti-F4/80 antibody (clone BM8; #11-4801; eBioscience, San Diego, CA,
USA) and phycoerythrin-conjugated anti-CD11c antibody (clone HL3;
#557401; 1:100; BD Pharmingen, San Diego, CA, USA) were also used.
Biochemical analyses
Serum LPS was quantified using a commercial kit based on the guidelines
provided by the supplier (Lal limulus amebocyte lysate assay; Cambrex Bio
Science, East Rutherford, NJ, USA). Serum free fatty acids (Biovision,
Milpitas, CA, USA), adiponectin (Biovision) and leptin (mouse leptin ELISA;
Abcam, Cambridge, MA, USA) were determined using commercial
detection kits. Serum triglycerides were quantified using a commercial
detection kit (Biovision). Serum IL-1β, IL-6 and TNF-α were examined with
commercial ELISA kits according to manufacturer’s instructions (R&D
Systems, Minneapolis, MN, USA).
Analysis of adipose tissues
Epididymal adipose tissues were fixed in 10% formalin overnight. Fixed
tissues were treated with paraformaldehyde and processed to obtain
paraffin-embedded tissues. Haematoxylin and eosin solution were used to
stain sections (5 μm), followed by observation under optical microscopy.
Adipocyte size was estimated using Adiposoft from the ImageJ software
(National Institutes of Health, USA).
Determination of energy and fat content in feces
Fecal lipids were extracted as before.27 In brief, a mixture of heptane/
diethylether/ethanol (1:1:1) was vortexed with dried feces once, followed
by two homogenization steps with a solution of heptane/diethylether/
ethanol/water (1:1:1:1). Collected supernatants were put into weighted
vials. The solvent was evaporated and the amount of lipids in each
supernatant was determined gravimetrically. Lipid amounts were
expressed as percentage of the weight of the starting sample. Energy in
feces (kJ g− 1 feces) was measured as reported previously using a bomb
calorimeter (Gallenkamp, Loughborough, UK).25
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Oral glucose and insulin tolerance tests
The mice used for the oral glucose tolerance test were fasted overnight.
Mice were given glucose by oral gavage (1 g kg− 1). Blood glucose was
quantified using a glucose meter (Johnson & Johnson, New Brunswick, NJ,
USA) from tail vein blood. To assess insulin tolerance, mice were fasted for
6 hours, prior to intraperitoneal injection of human insulin (0.3 units kg− 1;
Actrapid, Novo Nordisk, Bagsvaerd, Denmark). Serum blood glucose was
measured prior to insulin injection and every 30 min thereafter. Serum
insulin was quantified using a commercial ELISA kit (Mercodia, Uppsala,
Sweden).
Quantitative real-time reverse transcription polymerase chain
reaction
RNA level expression analysis was performed using total RNA isolated
using a commercial kit (Geneaid, New Taipei City, Taiwan). RNA was used
for reverse transcription with Quant II fast reverse transcriptase kit (Tools,
Taipei, Taiwan). The resulting cDNA (1.5 μl) was used as template and
mixed with 1 μl of target primers, 5 μl of KapaSYBR Fast Master Mix and
2.5 μl of water in each wells. PCR conditions were as follows: initial pre-
incubation at 95 °C for 10 min, 50 PCR cycles of 94 °C for 15 sec, 60 °C for
30 s, 72 °C for 30 s and then one melting curve cycle. The primers used are
listed in Supplementary Table 1. Data were analyzed with the Roche
LightCycler software (version 1.5.0, Roche Diagnostics, Indianapolis, IN,
USA). Relative quantification was performed using the comparative 2–ΔΔCT
method. Expression was normalized against glyceraldehyde 3-phosphate
dehydrogenase. Mean expression level of chow-fed mice was set at a
value of 1.
Western blotting
Adipose tissues (100 mg) were collected and homogenized in Pro-Prep
Protein Extraction Solution (Intron Biotechnology, Seoul, South Korea).
Equal amounts of proteins were separated on a 10% sodium dodecyl
sulfate-polyacrylamide gel and transferred onto polyvinylidenedifluoride
membranes (Immobilon TM-P; Millipore, Billerica, MA, USA). Membranes
were soaked with 5% non-fat milk for 1 h at room temperature in TBST
buffer (Tris 10 mM, NaCl 150 mM, pH 7.6, 0.1% Tween 20). Membranes were
incubated in 5% BSA containing primary antibodies at 4 °C overnight,
followed by incubation with horseradish peroxidase-conjugated secondary
antibody. Protein signals were detected using enhanced chemilumines-
cence (Millipore).
Flow cytometry analysis
Adipose tissues were minced into fine pieces and digested with
collagenase (Sigma, St Louis, MO, USA) in Krebs-Henseleit-HEPES buffer
(Sigma; pH 7.4) containing BSA (20 mg ml− 1) and glucose (2 mM). Samples
were passed through a 40 μm strainer mesh and centrifuged (1000 g) to
obtain stromal-vascular fractions. Cells were pretreated for 30 min with Fc
receptors (clone 2.4G2; Becton Dickinson, Franklin Lakes, NJ, USA). Cells
were stained for 30 min with primary antibodies or the matching control
isotypes at 4 °C. After two washing steps, the labeled cells were analyzed
by flow cytometry (FACSCalibur, Becton Dickinson) and the Kaluza
software (Beckman Coulter, Brea, CA, USA) was used to analyze flow
cytometry data. Macrophages were identified as F4/80 and CD11c double-
positive cells.
Gut microbiota analysis
Cecum feces were snap-frozen in liquid nitrogen and stored at –80 °C. Cellular
DNA was extracted using a fecal DNA isolation kit according to manufacturer’s
instructions (Qiagen, Redwood City, CA, USA). 16S rRNA gene containing the
V3–V4 regions was amplified using composite primers containing a unique 10-
base barcode to tag PCR products. The PCR mix (50 μl) was prepared as per
the instructions of the KAPA HiFi PCR kit (KAPA Biosystems, Wilmington, MA,
USA). PCR conditions comprised pre-denaturation at 95 °C for 3 min, followed
by 15–25 cycles of 98 °C for 20 s, 45 °C for 15 s and 72 °C for 15 s, and a final
extension of 72 °C for 1 min. Composite primers consisted of the forward
primer 5′-TCGTCGGCAGCGTCAGATGTGTATAAGAGACAGCCTACGGGNGGCW
GCAG-3′, which contains the Illumina forward overhang adaptor sequence
(underlined) and the universal bacterial primer 341F (italicized), and the
reverse primer 5′-GTCTCGTGGGCTCGGAGATGTGTATAAGAGACAGGAC
TACHVGGGTATCTAATCC-3′, which contains the Illumina reverse overhang
adaptor sequence (underlined) and the broad-range bacterial primer 805R
(italicized). V3–V4 amplicons were purified from the pooled replicate PCRs
using the QiaQuick PCR Purification Kit (Qiagen), followed by sequencing using
the Illumina Miseq pyrosequencer platform as per the instructions of the
manufacturer. The paired-end library was constructed with the Ovation
Ultralow DR Multiplex System 1-96 (NuGen, San Carlos, CA, USA) based on the
manufacturer’s instructions. Library concentration and quality were assessed
using Bioanalyzer 2100 (Agilent, Palo Alto, CA, USA) and a DNA 1000 lab chip
(Agilent). 16S amplicon libraries were sequenced with the 2×301+8 bp (index)
using Miseq Reagent kit v3 (600 cycles) on the Illumina MiSeq system following
the manufacturer’s instructions. Microbiota sequencing data were deposited
into NCBI’s Sequence Read Archive (accession# SPR106223).
Effective reads from all samples were selected from high-quality reads
and clustered into operational taxonomic units (OTUs) based on 97%
sequence similarity according to MiSeq standard operating procedures.28
In brief, high-quality reads were selected by removing sequences that
lacked V3–V4 primers or barcode sequences as well as sequences that
contained undetermined bases (42 bases) or a short variable region
(o90 bp) in the V3–V4 region. For reducing noise signals, a 50-bp sliding
window was used to reduce sequencing error in combination with an
average quality score of 35 within that window for sequence trimming.
High-quality sequences were aligned using the nearest alignment space
termination multi-aligner in SILVA-compatible database alignment,29 and
reads that were not aligned to the anticipated reference region were
deleted, followed by removal of chimera sequences identified using the
UCHIME algorithm.30 All reads were classified using a Bayesian classifier
with a homemade RDP database. Reads that could not be classified at the
kingdom level were deleted. Alpha diversity analysis including rarefaction
analysis and Shannon index were calculated using QIIME as described
before.31 UniFrac-based principal coordinate analysis was performed and
the phylogenetic tree was constructed by inserting the representative of
each OTU generated using QIIME.31 Based on published statistical
methods,22,25 the statistical significance of the separation among animal
groups in the principal coordinate analysis score plots was assessed using
multivariate analysis of variance test according to UniFrac matrix
differences. OTUs with statistically significant differences were analyzed
using Tukey’s post hoc test (SPSS, Chicago, IL, USA). Log10-transformed
relative abundance of each OTU was used to construct RDA models with
Canoco-assessed OTUs that were different between animal groups
(Microcomputer Power, Ithaca, NY, USA). Statistical significance was
determined using the Monte Carlo Permutation Procedure with 499
random permutations.
Statistical analysis
Data obtained from three independent experiments are shown as
means± s.d. Differences in absolute body weight and body weight gain
were determined using two-way analysis of variance Bonferroni post hoc
test. Data sets involving more than two groups were analyzed using
Bonferroni one-way analysis of variance followed by post hoc test. Next-
generation sequencing analysis was assessed using Tukey’s honest
significant difference post hoc test. P-values below 5% were considered
statistically significant. The two-stage procedure of Benjamini et al.32 was
used to control the false discovery rate.
RESULTS
WEAC reduces HFD-induced obesity in mice
To study the effects of A. cinnamomea on obesity, we used an
animal model of diet-induced obesity in which mice were fed with
a HFD for 8 weeks.25 HFD feeding for this period led to significant
increases in body weight, epididymal and subcutaneous fat
accumulation, adipocyte size and serum triglyceride levels
compared with the control chow-fed group (Figures 1a–g).
Notably, WEAC supplementation significantly decreased body
weight and fat accumulation in HFD-fed mice (Figures 1a–g). After
8 weeks of feeding, the mean body weight of the HFD group was
39.8 ± 1.2 g compared with 35.8 ± 1.3 g for the HFD+1% WEAC
group (Figure 1a), corresponding to a difference of 4 g or 10% of
body weight (Po0.0001). Although the 0.1% WEAC treatment
reduced body weight gain in a statistically significant manner after
7 weeks of feeding (Figure 1b), 1% WEAC reduced body weight
and body weight gain after 6 weeks of feeding (Figures 1a and b).
WEAC treatments reduced both epididymal and subcutaneous fat
after 8 weeks of feeding (Figures 1d and e), although the effects of
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0.1% WEAC on subcutaneous fat did not reach statistical
significance (Figure 1e). WEAC treatments reduced adipocyte size
within epididymal adipose tissues (EAT) (Figure 1f, adipocyte size
distribution is shown in the bottom panel). The 1% WEAC
treatment also reduced serum triglyceride level compared with
control HFD (Figure 1g). Of note, feces energy, food intake and
stool fat contents showed no statistically significant differences
between HFD groups (Supplementary Figure 1), indicating that
the effects of WEAC on body weight and lipid accumulation were
not due to reduction in appetite, lipid absorption, or energy
extraction. These results indicate that WEAC supplementation
reduces body weight gain and fat accumulation in obese mice.
WEAC reduces pro-inflammatory cytokines in HFD-fed mice
Previous studies have shown that the adipose tissues of obese
animals secrete higher levels of pro-inflammatory cytokines
compared with the adipose tissues of lean animals.20 To
determine whether WEAC reduces inflammation, we monitored
mRNA expression levels of pro-inflammatory cytokines in EAT after
8 weeks of HFD feeding and WEAC supplementation. TNF-α, IL-1β
and IL-6 expression levels were higher in HFD-fed mice compared
with chow-fed mice (Figures 2a–c). WEAC supplementation (1%)
significantly reduced cytokine expression levels compared with
the HFD group (Figures 2a–c). Similar to the results obtained for
mRNA expression, WEAC supplementation reduced TNF-α, IL-1β
and IL-6 protein levels in the blood of HFD-fed mice (Figures 2d–f).
These results indicate that WEAC supplementation reduces
inflammation markers in obese mice.
WEAC reduces inflammation in adipose tissues of HFD-fed mice
One important characteristic of obesity is the infiltration and
activation of immune cells in adipose tissues.33 MCP-1 is a pro-
inflammatory cytokine that recruits and activates macrophages in
adipose tissues of obese animals.34 Accordingly, mRNA expression
levels of MCP-1 and the macrophage biomarker F4/80 were
significantly elevated in EAT of HFD-fed mice compared with
chow-fed mice (Figures 3a and b). WEAC supplementation (1%)
reduced F4/80 and MCP-1 gene expression levels in HFD-fed mice
(Figures 3a and b). We further examined the amount of double-
positive F4/80-CD11c macrophages recruited in EAT using flow
cytometry analysis. Our results showed that WEAC reduced the
infiltration of activated macrophages in a dose-dependent
manner in EAT of HFD-fed mice (Figure 3c).
Next, we examined the effects of WEAC supplementation on
LPS blood levels. Although the HFD induced a large increase of
serum endotoxin, WEAC supplementation (1%) reduced endotoxin
level in a statistically significant manner (Figure 3d). LPS has
previously been shown to activate JNK and NF-κB signaling
pathway and increase expression of pro-inflammatory cytokines in
activated macrophages and adipose tissues.35 We examined
whether this pathway was affected by WEAC supplementation
in EAT. Phosphorylation (and activation) of JNK was reduced by
WEAC (1%) compared with HFD-fed mice (Figure 3e), whereas the
amount of IκB-α (an inhibitor of the transcription factor NF-κB)
increased in WEAC-treated mice (Figure 3f). Based on these results,
we conclude that WEAC supplementation reduces inflammation
by decreasing infiltration of activated macrophages and LPS-
induced NF-κB and JNK signaling in adipose tissues.
WEAC reduces insulin resistance in HFD-fed mice
Previous studies have shown that endotoxemia and chronic
inflammation can lead to insulin resistance and type 2 diabetes in
mice.19,20 As expected, WEAC supplementation (1%) reduced
fasting insulin and glucose levels in HFD-fed mice (Figures 4a and
b). Moreover, WEAC reduced glucose intolerance and increased
insulin sensitivity in HFD-fed mice submitted to oral glucose
tolerance test (Figure 4c) and insulin tolerance test, respectively
(Figure 4d; graphs showing the area under the curves, or AUC, are
also shown in the panels on the right). Previous work35 has shown
that endotoxin-induced activation of JNK and NF-κB signaling
pathway may decrease phosphorylation of Akt downstream of the
insulin receptor, leading to insulin resistance. Consistent with the
insulin-sensitizing effects shown above, WEAC supplementation
induced the accumulation of phosphorylated Akt in a dose-
dependent manner in EAT of HFD-fed mice (Figure 4e). WEAC
therefore reduces insulin resistance in obese mice.
WEAC modulates the expression of leptin and adiponectin in
HFD-fed mice
Leptin and adiponectin are adipokines that have an important role
in modulation of obesity, insulin resistance and related inflam-
matory disorders.36 We examined whether the expression and
production of leptin and adiponectin in EAT is affected by WEAC
supplementation. We observed that leptin expression was
elevated in HFD-fed mice compared with chow-fed mice, whereas
WEAC reduced leptin expression in HFD-fed mice (Supplementary
Figure 2a). In contrast to leptin, adiponectin expression level was
lower in HFD-fed mice compared with the chow group, and WEAC
supplementation increased adiponectin expression
(Supplementary Figure 2b). Of note, WEAC (1%) reversed the
effects of the HFD on leptin and adiponectin serum protein levels
(Supplementary Figure 2c and d).
The AMPK enzyme, which acts downstream of the adiponectin
receptor, reduces inflammation and insulin resistance in HFD-fed
mice.36 As WEAC induced the expression and production of
adiponectin in EAT and the serum of HFD-fed mice
(Supplementary Figure 2b and d), we examined the phosphorylation
status of AMPK in EAT. Phosphorylated (active) AMPK level was
reduced in HFD-fed mice, whereas WEAC treatment increased the
level of this protein (Supplementary Figure 2e). These results suggest
that WEAC supplementation may reduce inflammation and insulin
resistance by modulating the activities of leptin and adiponectin.
WEAC regulates expression of genes involved in fatty-acid
metabolism
Previous studies have shown that the expression of genes involved
in fatty-acid biosynthesis, such as acetyl-CoA carboxylase-1 (ACC-1),
fatty-acid synthase (FAS) and sterol regulatory element-binding
protein-1c (SREBP-1c), are upregulated in adipose tissues of HFD-fed
mice, whereas fatty-acid catabolism genes, such as PPAR-γ
co-activator 1α (PGC-1α), are downregulated.37 AMPK was also
reported to control lipid metabolism by regulating the expression of
these four genes.38 Notably, WEAC supplementation (1%) reduced
expression of ACC-1, FAS and SREBP-1c in EAT of HFD-fed mice,
whereas it increased the expression of PGC-1α (Supplementary
Figure 3a–d). Previous work showed that free fatty acid levels
increase in the blood of obese animals and may enhance
inflammation by activating Toll-like receptor-4 on adipocytes and
macrophages.39 Notably, WEAC supplementation (1%) reduced
serum free fatty acid levels in HFD-fed mice (Supplementary
Figure 3e). Based on these results, WEAC may reduce lipid
accumulation by regulating the expression of genes involved in
lipid metabolism in HFD-fed mice.
WEAC enhances antimicrobial peptide production and maintains
intestinal barrier integrity
Antimicrobial peptides produced by intestinal cells have an
important role in maintaining gut microbiota homeostasis and
physical segregation of commensal microorganisms from host
tissues.40 Previous studies have shown that the expression of
antimicrobial peptides, such as Reg3g, lysozyme C and PLA2g2
(phospholipase A2 group II), is reduced in HFD-fed mice.24
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Notably, we observed that WEAC (1%) increased the expression of
Reg3g and lysozyme C in the ileum of HFD-fed mice, whereas
PLA2g2 was unaffected (Supplementary Figure 4a–c). We also
examined whether WEAC modulates intestinal tight junction
proteins, which maintain intestinal barrier integrity. Although HFD
feeding reduced expression of zonula occludens-1 and occludin
in the ileum, WEAC supplementation increased the expression
level of these proteins (Supplementary Figure 4d and e).
Consistent with the reduced blood endotoxin level noted above
in WEAC-treated mice (Figure 3d), these findings suggest that
WEAC attenuates the effects of HFD on host antimicrobial defense
and intestinal barrier integrity.
WEAC alters the diversity and composition of the gut microbiota
in HFD-fed mice
Previous studies have shown that the gut microbiota is involved in
the development of lean and obese phenotypes in animals.17
Reduced bacterial richness and diversity have been observed in
obese humans and mice.25,41 We examined whether WEAC may
alter the composition and diversity of the gut microbiota by
analyzing bacterial 16S rRNA (V3–V4 DNA region) in cecal feces
using next-generation sequencing. After removing unqualified
sequences (see Methods), a total of 5 063 884 raw reads and an
average of 133 260 ± 31 937 reads per sample were obtained.
A total of 2 379 449 effective reads was generated, with each fecal
sample (n= 4 for chow, HFD and HFD+0.1%; n= 3 for HFD+1%)
producing an average of 62 617 ± 15 009 effective reads. Samples
with a low number of effective reads (o3000) were discarded.
Rarefaction analysis indicated that the sequencing depth covered
rare and new phylotypes and broad bacterial diversity.
As shown in Figures 5a–c, the observed species and the two
indexes reflecting species richness and diversity (Chao-1 index
and Shannon index, respectively) were reduced in HFD-fed mice
compared with chow-fed mice, consistent with previous studies.25
In contrast, the richness and diversity of the gut microbiota of
HFD-fed mice were enhanced in a statistically significant manner
by 1% WEAC supplementation (Figures 5a–c). UniFrac-based
principal coordinates analysis revealed distinct clustering of
microbiota composition for each treatment (Figure 6a). In
Figure 2. WEAC reduces pro-inflammatory cytokine expression and production in HFD-fed mice. Mice were treated as in Figure 1. Relative
expression of TNF-α (a), IL-1β (b), and IL-6 (c) in EAT was assessed using qRT-PCR. Expression was normalized against GAPDH. TNF-α (d), IL-1β
(e) and IL-6 (f) protein levels in the serum of chow-fed and HFD-fed mice were determined using ELISA (n= 5 for each group). Data are shown
as means± s.d. Graph bars with different letters on top correspond to statistically significant results (Po0.05) based on Bonferroni post hoc
one-way ANOVA analysis.
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Figure 3. WEAC reduces macrophage infiltration, serum endotoxin and pro-inflammatory signaling pathways in HFD-fed mice. Effects of
WEAC on mRNA expression levels of F4/80 (a) and MCP-1 (b) in EAT as assessed by qRT-PCR (n= 5 for each group). Mice were treated as in
Figure 1. Relative mRNA expression levels represent means± s.d. Expression level was normalized against GAPDH. Macrophage infiltration in
EAT (c) was determined by flow cytometry; quantification is shown in the panel on the right. Effect of WEAC on serum endotoxin (LPS) (d) was
assessed using the limulus amebocyte lysate assay kit and expressed as means± s.d. of serum endotoxin units per ml. Effects of WEAC on
P-JNK (e) and IκB-α (f) was assessed using Western blotting. In e, the anti-JNK antibodies (P-JNK and T-JNK) react against the two JNK isoforms
p54 and p46. In e and f, relative band intensities for P-JNK and IκB-α were determined by densitometry analysis (values shown on top of each
blot; for P-JNK, the values represent the average intensity of the two bands). Graph bars with different letters on top correspond to statistically
significant results (Po0.05) based on Bonferroni post hoc one-way ANOVA analysis.
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agreement with previous studies, taxonomic profiling showed that
the ratio of Firmicutes to Bacteroidetes (F/B ratio) increased
following HFD feeding (Figure 6b). In contrast, WEAC treatment
(1%) reduced the F/B ratio to a level similar to that observed in
chow-fed mice (Figure 6b).
Compared with HFD-fed mice, WEAC supplementation (1%)
increased the level of several bacterial species, some of which
have been shown to produce beneficial effects on obesity and
inflammation, including Streptococcus spp.,42 Eubacterium spp.,43
Eggerthella lenta,44 Clostridium IV (Clostridium methylpentosum)25
and A. muciniphila18 (Figure 6c; see also Supplementary Table 2).
In contrast, Ruminococcaceae and Lachnospiraceae at the family
level and Clostridium scindens and Clostridium cocleatum at the
species level were reduced by WEAC treatment (1%) compared
with the HFD group (Figure 6c and Supplementary Table 2).
Together, these results indicate that WEAC administration alters
Figure 4. WEAC supplementation reduces HFD-induced insulin resistance. Effects of WEAC on fasting insulin (a), fasting glucose (b), oral
glucose tolerance test (c), insulin tolerance test (d) and phosphorylation of Akt in EAT (e) (n= 5 for each group). T-Akt refers to total Akt. Insulin
and glucose levels were monitored using commercial ELISA kit and a glucose meter, respectively. The areas under the curve (AUC) in (c, d)
(right panels) are also shown. Graph bars with different letters on top correspond to statistically significant results (Po0.05) based on
Bonferroni post hoc one-way ANOVA analysis. In e, relative P-Akt band intensities determined by densitometry analysis are shown on top.
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the gut microbiota community, an observation that may explain at
least in part the beneficial effects of this extract on obesity and
inflammation.
DISCUSSION
Although previous studies have shown that A. cinnamomea may
reduce lipid accumulation in rodents,12–14 the mechanism under-
lying this effect and whether the mushroom may modulate the
composition of the gut microbiota or intestinal integrity remained
unclear. In the present study, we showed that WEAC reduces body
weight and obesity-associated metabolic disorders in HFD-fed
mice by affecting a wide range of physiological processes,
including lipid storage, adipokine production, macrophage
infiltration, insulin sensitivity, maintenance of intestinal integrity
and gut microbiota composition. Our findings suggest that
A. cinnamomea may represent a new anti-obesogenic and
antidiabetic treatment.
Our previous study25 showed that G. lucidum possesses anti-
obesogenic and antidiabetic properties similar to the effects
described here for A. cinnamomea. In the case of G. lucidum, a
fraction containing high molecular weight polysaccharides
produced anti-obesogenic and antidiabetic effects like those
of the water extract studied here. Chen et al.45 reported that
A. cinnamomea mycelium contains 8% polysaccharides. On the
other hand, our mycelium contains 1.5% polysaccharides
(before water extraction), suggesting that the effects described
here may be due to other compounds, a possibility which
requires further investigation. Of note, toxicological studies
showed that A. cinnamomea produces no pathological abnorm-
alities in Sprague–Dawley rats and BALB/c mice following
consumption of high doses for 90 days (3000 mg kg − 1 per day
and 1666.67 mg kg − 1 per day, respectively).45,46 These
Figure 5. Diversity analysis of WEAC-treated gut microbiota. Observed species (a), Chao-1 index (b) and Shannon index (c) of fecal samples
from mice fed with chow (n= 4), HFD (n= 4), HFD+0.1% WEAC (n= 4) or HFD+1% WEAC (n= 3). Graph bars with different letters on top
correspond to statistically significant results (Po0.05) based on Bonferroni post hoc one-way ANOVA analysis.
Antrodia cinnamomea reduces weight in obese mice
C-J Chang et al
239
International Journal of Obesity (2018) 231 – 243
observations suggest that A. cinnanomea may be suitable for
long-term use.
We observed that WEAC supplementation reduces the expres-
sion of enzymes involved in lipid synthesis (ACC-1, FAS and
SREBP-1c) in EAT of HFD-fed mice, whereas it increases the
expression of proteins involved in lipid oxidation (PGC-1α). ACC-1
is a biotin-dependent enzyme that catalyzes the irreversible
carboxylation of acetyl-CoA to produce malonyl-CoA, which is a
substrate for FAS to generate palmitate.47 Upon activation,
SREBP-1c translocates from the cytosol into the nucleus, where
it acts as a transcription factor and binds to specific sterol
regulatory DNA sequences, thereby upregulating the synthesis of
enzymes involved in sterol biosynthesis.48 Reduced expression of
these three proteins may be involved in the reduced fat
accumulation and fatty acid levels observed in WEAC-treated
mice (Figure 1 and Supplementary Figure 3). In contrast, PGC-1α
interacts with the nuclear receptor PPAR-γ, resulting in recruit-
ment of other transcription factors and co-activators.48 As PGC-1α
is a key regulator of energy metabolism, upregulation of this
transcriptional co-activator following WEAC supplementation
(Supplementary Figure 3d) is consistent with increased energy
consumption.49 These results suggest that WEAC may reduce fat
accumulation and blood lipid levels by modulating enzymes and
proteins involved in lipid metabolism.
The Akt enzyme, also known as protein kinase B, is a serine/
threonine protein kinase that has a key role in several cellular
processes, including glucose metabolism, cell proliferation and cell
migration.50 Previous studies have shown that over-production of
pro-inflammatory cytokines such as TNF-α, IL-1β, IL-6 and MCP-1
in obese animals may be responsible for the development of
chronic inflammation and insulin resistance, owing at least in part
to deregulation of the Akt pathway in muscle cells and immune
cells.35 In the present study, we observed that WEAC supplemen-
tation reduces the production of pro-inflammatory cytokines
(Figure 2) and enhances phosphorylation of Akt (Figure 4e), which
may explain the improved insulin sensitivity observed in the
treated mice.
Following stimulation of Toll-like receptors by pathogen-
associated molecular patterns, such as peptidoglycan and LPS
from bacteria, intestinal Paneth cells can produce Reg3g.40
Figure 6. WEAC supplementation alters microbiota composition in HFD-fed mice. Microbiota composition in feces of chow-fed mice (n= 4),
HFD mice (n= 4) treated with 0.1% (n= 4) or 1% WEAC (n= 3) was analyzed using next-generation sequencing and bioinformatics analysis. (a)
UniFrac-based PCoA plots. (b) Bacterial taxonomic profiling of intestinal bacteria from different mouse groups at the phylum level. (c) Heat
map showing the abundance of bacterial taxa significantly altered by WEAC in HFD-fed mice. Bacterial taxa information (phylum, class, order,
family, genus and species) is shown in the right panel. White circles and black diamonds indicate the bacterial taxa that respectively increased
and decreased in chow-fed and HFD+WEAC-fed groups compared with the HFD-fed group. Black stars represent bacterial taxa whose
abundance in chow-fed mice was altered by HFD and reversed by WEAC.
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Previous work showed that Reg3g-deficient mice have an altered
intestinal mucus distribution and show signs of mucosal
inflammation in response to the gut microbiota,51 findings that
highlight the important role of Reg3g in controlling gut
microbiota homeostasis. Lysozyme C functions by attacking
peptidoglycans found in the bacterial cell wall. The level of this
protein correlates inversely with body weight and its reduction
appears to represent an important alteration that affects the
microbiota of obese individuals.52 In contrast, the enzyme Pla2g2
releases fatty acids from phospholipids found in the cell
membrane and can induce the production of pro-inflammatory
eicosanoids.53 Our results showed that WEAC increased the
expression of Reg3g and lysozyme C in the ileum of HFD-fed
mice, whereas no effect was observed for PLA2g2 (Supplementary
Figure 4). These results indicate that WEAC enhances host
antimicrobial defense mechanisms, which may further explain
the modulatory effects of WEAC on the gut microbiota.
Macrophages can exhibit either pro- or anti-inflammatory
phenotypes and are generally grouped as M1 or M2
phenotypes.33 M1 macrophages secrete pro-inflammatory cyto-
kines, such as TNF-α, IL-6, and IL-1β, and are involved in the pro-
inflammatory response. In contrast, M2 macrophages mainly
secrete anti-inflammatory cytokines, such as IL-10, TGF-β and IL-4,
and are involved in wound healing and termination of the
inflammatory response.33 Adipose tissue macrophages refer to
tissue-resident macrophages found in adipose tissues. In both
humans and rodents, macrophages may accumulate in adipose
tissues upon increased body weight, and may act as major
contributors to tissue inflammation and insulin resistance in obese
individuals.33 Besides, the number of macrophages within adipose
tissues depends on the metabolic status of the host. Previous work
has shown that the percentage of macrophages within adipose
tissues ranges from 10% in lean mice and humans to 50% in
extremely obese, leptin-deficient mice (almost 40% in obese
humans).54 The increased number of adipose tissue macrophages,
namely the pro-inflammatory M1 macrophages, correlates with
increased production of pro-inflammatory cytokines by adipose
tissues, a phenomenon that might contribute to the pathological
effects of weight gain and obesity.33 Cytokines and chemokines
such as MCP-1 are also involved in regulating migration and
infiltration of monocytes/macrophages. In addition, pro-
inflammatory cytokines such as TNF-α are mostly produced by
macrophages rather than adipocytes.54 It has been proposed that
pro-inflammatory cytokines and macrophages may contribute to
the development of insulin resistance and type 2 diabetes in
obese animals. Importantly, WEAC supplementation reduced the
levels of pro-inflammatory cytokines and adipose tissue macro-
phages (Figures 2 and 3), which may also contribute to the
beneficial effect of the extract on obesity.
WEAC treatment enhanced adiponectin signaling, as shown by
activation of AMPK (Supplementary Figure 2). AMPK is involved in
many important physiological functions in animals and humans,
including activation of fatty-acid oxidation in the liver and
muscles, increased production of ketone bodies, reduced choles-
terol production, enhanced muscle glucose uptake and modula-
tion of insulin secretion by pancreatic beta-cells.55 Many of the
effects of WEAC, including reduced body weight and fat
accumulation (Figure 1) and amelioration of insulin resistance
(Figure 4), may be attributed at least in part to AMPK activation.
Effective preventive or therapeutic strategies that can reduce
the development of chronic low-grade inflammation and insulin
resistance would be beneficial to prevent type 2 diabetes and
obesity. Many prebiotics are non-digestible polysaccharides that
are fermented by bacteria in the colon to produce short-chain
fatty acids that can be absorbed into the blood in order to
regulate various physiological functions, including lipid metabo-
lism and immunity.26 We have previously reported that high
molecular weight polysaccharides purified from a water extracts of
G. lucidum reduce body weight and obesity-related disorders in
HFD-fed mice.25 In the present study, we observed that WEAC
produced significant changes on the gut microbiota of HFD-fed
mice (Figures 5 and 6). WEAC significantly reduced the Firmicutes-
to-Bacteroidetes ratio in HFD-fed mice (Figure 6b), consistent with
previous observations of mushroom-derived prebiotics.25 WEAC
supplementation also reversed the effects of HFD on several
bacterial taxa associated with weight loss (Figure 6c and
Supplementary Table 2). Previous studies have shown that the
gut microbiota is closely involved in the development of obesity in
animals.17 For example, an increased number of C. methylpento-
sum (Clostridium IV) was observed following treatment with
G. lucidum polysaccharides.25 Moreover, in rats fed with a HFD or a
high-sucrose diet rat, treatment with trans-resveratrol increased
C. methylpentosum and reduced aberrant phenotypes in the gut
microbiota.56 Another study showed that A. muciniphila can
reduce obesity and restore intestinal barrier functions by
regulating inflammation and lipid metabolism.18 Upon treatment
with the prebiotic oligofructose, A. muciniphila also increased
intestinal Reg3g expression.18 Furthermore, Eubacterium spp.
induced by prebiotic oligosaccharides produced beneficial effects
on animals.43 Eggerthella lenta was enriched by red wine
polyphenols that improve metabolic syndrome in patients.44
Streptococcus spp. are also considered as having probiotic
properties.42 Our results demonstrate that WEAC supplementation
enriches C. methylpentosum, A. muciniphila, Eubacterium spp. and
Streptococcus spp. in HFD-fed obese mice (Figure 6c). These results
suggest that the effects of WEAC may be due, at least in part, to an
increase in these gut bacterial species.
On the other hand, several bacterial species have been
associated with a pro-inflammatory response and weight gain.
For example, Bacteroides caccae is an opportunistic pathogen
whose level correlates with type 2 diabetes mellitus and
inflammation.57 C. cocleatum is positively correlated with LPS
levels and progression of liver disease in streptozotocin-HFD-fed
animals.58 Clostridium scindens is enriched by HFD feeding and is
associated with increased amounts of deoxycholic acid, which
may cause inflammation and liver cancer.59 In addition, Rumino-
coccaceae and Lachnospiraceae at the family level were both
enhanced in HFD-fed mice.60 Of note, WEAC supplementation
reduced the levels of these bacteria (Figure 6c and Supplementary
Table 2). Therefore, WEAC may prevent HFD-induced obesity and
complications by modulating the composition of the gut
microbiota in multiple ways.
Taken together, our results indicate that A. cinnamomea
possesses anti-obesogenic, antidiabetic and anti-inflammatory
properties in an animal model of diet-induced obesity. Further
studies are needed to identify the active compounds responsible
for these effects and to test the effects of A. cinnamomea in
humans.
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